Saxendas Pen Injectable Weights Pen Saxend Slimmings Increase Satietys Lose Fas

• Material: Lipolysis
• Ethylene Oxide Sterilization: Ethylene Oxide Sterilization
• Quality Guarantee Period: Two Years
• Group: Adult
• Logo Printing: With Logo Printing
• Function: Injection
• Model NO.: 3ml
• Transport Package: Box
• Specification: 1.5ml 3ml
• Trademark: ozempics
• Origin: China
• Production Capacity: 10000

Product Description

 

Model Number	3ml
Brand Name	sax endas
origin	korea
Small Orders	Accepted

 

What is Sax  endas?

Saxe nda is an FDA-approved, prescription injectable medicine that, when used with a low-calorie meal plan and increased physical activity, may help some adults with excess weighta who also have weight-related medical problems (such as high blood pressure, high cholesterol, or type 2 diabetes), or obesity to lose weight and keep it off. Sax enda is not for the treatment of type 2 diabetes and should not be used with Victoza or any other GLP-1 receptor agonist. It is not known if Sax enda is safe and effective when taken with other prescription, over-the-counter, or herbal weight-loss products. Click here for the full indication.

Be sure to look up your co-pay and ask your health care provider if Sax enda is right for you.

What are the benefits of using Ozempics?

1. Control blood sugar to help you achieve your HbA1c goal

2. Help you lose weight

3. Help reduce your risk of cardiovascular disease

4. Helps reduce your risk of kidney disease

Trade name: OZEMPICs

English name: Semaglutide

Standard: 1.5ml 3ml

Manufacturer: Novo Nordisk

Dosage and administration method

For first use, start at 0.25 mg once a week. After 4 weeks, the dose was increased to 0.5mg once a week. If additional glycemic control is required after at least 4 weeks, increase to 1mg weekly.

Smiglutide is a subcutaneous injection, which you can optionally inject into the abdominal wall, thigh or upper arm; Smiglutide only needs to be used once a week, and should be injected on the same day of the week, not according to the time of meal.

matters need attention

Pancreatitis: Has been reported in clinical trials. If pancreatitis is suspected, discontinue the drug immediately. If pancreatitis is confirmed, do not start over.

• Diabetic retinopathy complications: reported in clinical trials. Patients with a history of diabetic retinopathy should be monitored.

• Do not share OZEMPICs pens between patients, even after changing needles.

• Hypoglycemia: When O-ZEMPIC® is used with insulin secretagogues or insulin, consider lowering the dose of the secretagogue or insulin to reduce the risk of hypoglycemia.

• Acute Kidney Injury: Monitor renal function in patients with renal insufficiency with severe gastrointestinal adverse effects.

• Allergic Reactions: Discontinue OZEMPICs® if suspected and seek immediate medical advice